Given that selective HDAC3 inhibitor RGFP966 exhibited a pronounced anti‐cancer effect in hematological malignancies (Matthews et al, 2015), we sought to determine whether RGFP966 inhibits cell growth of solid tumors such as prostate cancer. Here, HDAC3 is linked to cancer.